FindTrial
Sign In

Palliative Care in blood cancers undergoing CAR-T Cell therapy : A pilot single-arm single-center prospective observational study

Integration of specialist palliative care in relapsed/refractory hematologic malignancies undergoing Chimeric Antigen Receptor (CAR)-T cell therapy: A pilot single-arm single-center prospective observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/086476
Enrollment
50
Registered
2025-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C969- Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified Health Condition 2: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients of age more than and equal to 18 years Relapsed or Refractory hematologic malignancies Patients planned for CAR-T Cell Therapy Patient has been informed of the diagnosis treatment and prognosis of disease Able to communicate in English Marathi Hindi Bengali Capable of giving a written informed consent

Exclusion criteria

Exclusion criteria: Patients planned for best supportive care alone Patients should not have cognitive impairment preventing patients from comprehending questionnaire

Design outcomes

Primary

MeasureTime frame
Feasibility of the study will be assessed by the proportion of patients who complete the questionnaireTimepoint: Baseline (T0) 1 Day prior to initiating CAR-T cell therapy (T1) Day 28 after CAR-T cell therapy (T2)—

Secondary

MeasureTime frame
1)Change in FACT-Leu & FACT-Lym score at T0,T1,T2 2)Symptom profile in this population using Edmonton Symptom Assessment System ESAS r CS at T0 T1 & T2 Timepoint: baseline (T0) 1 day prior to initiating CAR T cell therapy (T1) Day 28 after CAR T Cell therapy (T2)—

Countries

India

Contacts

Public ContactDr Priyanka Shete

Tata Memorial Hospital

jukd2000@yahoo.co.uk241770007148

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026